Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.

• A. Gomaa ^[1] ; N. Allam ^[1] ; I. Waked ^[1]
  1. [1] National Liver Institute, Menoufia University, Shebeen El-Kom, Egypt
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 3, 2021, págs. 199-208
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Effective oral combination regimens have been approved for treatment of hepatitis C virus (HCV) infection and demonstrated high cure rates in different HCV genotypes. These direct-acting agents target a variety of HCV proteins, including HCV-NS5A (nonstructural protein 5A). Ravidasvir hydrochloride, a potent pan-genotypic HCV-NS5A inhibitor approved in Egypt for treatment of HCV genotype 4 (G4), demonstrated impressive efficacy, safety profiles and a high barrier to resistance in multiple clinical trials when used as a key component in combination with other direct-acting agents in treating patients with HCV-G1.